Benzetimide HCl, formerly known as EINECS 227-072-8, Spasmentral, and Dioxatrine, is a muscarinic acetylcholine receptor antagonist. Benzetimide HCl has been utilized to treat parkinsonism brought on by neuroleptics. The enantiomer of dexetimide is benzetimide.
Physicochemical Properties
| Molecular Formula | C23H27CLN2O2 |
| Molecular Weight | 398.931 |
| Exact Mass | 398.176 |
| Elemental Analysis | C, 69.25; H, 6.82; Cl, 8.89; N, 7.02; O, 8.02 |
| CAS # | 5633-14-7 |
| Related CAS # | 14051-33-3;5633-14-7 (HCl); |
| PubChem CID | 21846 |
| Appearance | White to off-white solid powder |
| Boiling Point | 543.9ºC at 760 mmHg |
| Flash Point | 282.7ºC |
| LogP | 4.289 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 28 |
| Complexity | 529 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(C(C1CCN(CC2=CC=CC=C2)CC1)(C3=CC=CC=C3)CC4)NC4=O.[H]Cl |
| InChi Key | XSOOSXRNMDUWEM-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C23H26N2O2.ClH/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18;/h1-10,20H,11-17H2,(H,24,26,27);1H |
| Chemical Name | 3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione;hydrochloride |
| Synonyms | EINECS 227-072-8; Spasmentral; Benzetimide Hydrochloride; Dioxatrine; Benzetimide HCl |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Characterization of muscarinic receptors in rat kidney. Eur J Pharmacol. 1993 Jan 4;244(1):21-7. |
| Additional Infomation | A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide. |
Solubility Data
| Solubility (In Vitro) | DMSO: ≥ 32 mg/mL (~80.2 mM) H2O: ~16.7 mg/mL (~41.8 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5067 mL | 12.5335 mL | 25.0671 mL | |
| 5 mM | 0.5013 mL | 2.5067 mL | 5.0134 mL | |
| 10 mM | 0.2507 mL | 1.2534 mL | 2.5067 mL |